Body mass index and prognosis in patients hospitalized with acute exacerbation of chronic obstructive pulmonary disease

Journal of Cachexia, Sarcopenia and Muscle

Volumn 2, Issue 2, 2011, Pages 81-86

  Lainscak, Mitja ^a,b   von Haehling, Stephan ^b   Doehner, Wolfram ^b   Sarc, Irena ^a   Jeric, Tina ^a   Ziherl, Kristina ^a   Kosnik, Mitja ^a   Anker, Stefan D ^b,c   Suskovic, Stanislav ^a  

^a UNIVERSITY CLINIC OF RESPIRATORY AND ALLERGIC DISEASES   (Slovenia)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

Body mass index; Cachexia; Chronic obstructive pulmonary disease; Survival

Indexed keywords

ADULT; AGED; ARTICLE; BODY MASS; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE ASSOCIATION; DISEASE EXACERBATION; FEMALE; FOLLOW UP; HOSPITAL CARE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT;

EID: 80054999904     PISSN: 21905991     EISSN: 21906009     Source Type: Journal    
DOI: 10.1007/s13539-011-0023-9     Document Type: Article

References (39)

1. von Haehling S, Anker SD. Cachexia as a major underestimated and unmet medical need: facts and numbers. J Cachexia Sarcopenia Muscle. 2010; 1: 1-5.
2. Doehner W, von Haehling S, Anker SD, Lainscak M. Neurohormonal activation and inflammation in chronic cardiopulmonary disease: a brief systematic review. Wien Klin Wochenschr. 2009; 121: 293-6.
3. Schols AM, Slangen J, Volovics L, Wouters EF. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998; 157: 1791-7.
4. Davos CH, Doehner W, Rauchhaus M, Cicoira M, Francis DP, Coats AJ, et al. Body mass and survival in patients with chronic heart failure without cachexia: the importance of obesity. J Card Fail. 2003; 9: 29-35.
5. Kalantar-Zadeh K, Abbott KC, Salahudeen AK, Kilpatrick RD, Horwich TB. Survival advantages of obesity in dialysis patients. Am J Clin Nutr. 2005; 81: 543-54.
6. Kalantar-Zadeh K, Horwich TB, Oreopoulos A, Kovesdy CP, Younessi H, Anker SD, et al. Risk factor paradox in wasting diseases. Curr Opin Clin Nutr Metab Care. 2007; 10: 433-42.
7. Wagner PD. Possible mechanisms underlying the development of cachexia in COPD. Eur Respir J. 2008; 31: 492-501.
8. Landbo C, Prescott E, Lange P, Vestbo J, Almdal TP. Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999; 160: 1856-61.
9. Groenewegen KH, Schols AM, Wouters EF. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest. 2003; 124: 459-67.
10. Connors Jr AF, Dawson NV, Thomas C, Harrell Jr FE, Desbiens N, Fulkerson WJ, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med. 1996; 154: 959-67.
11. Gunen H, Hacievliyagil SS, Kosar F, Mutlu LC, Gulbas G, Pehlivan E, et al. Factors affecting survival of hospitalised patients with COPD. Eur Respir J. 2005; 26: 234-41.
12. Hallin R, Gudmundsson G, Suppli Ulrik C, Nieminen MM, Gislason T, Lindberg E, et al. Nutritional status and long-term mortality in hospitalised patients with chronic obstructive pulmonary disease (COPD). Respir Med. 2007; 101: 954-1960.
13. Tsimogianni AM, Papiris SA, Stathopoulos GT, Manali ED, Roussos C, Kotanidou A. Predictors of outcome after exacerbation of chronic obstructive pulmonary disease. J Gen Intern Med. 2009; 24: 1043-8.
14. Ranieri P, Bianchetti A, Margiotta A, Virgillo A, Clini EM, Trabucchi M. Predictors of 6-month mortality in elderly patients with mild chronic obstructive pulmonary disease discharged from a medical ward after acute nonacidotic exacerbation. J Am Geriatr Soc. 2008; 56: 909-13.
15. Sarc I, Jeric T, Ziherl K, et al. Adherence to treatment guidelines and long-term survival in hospitalized patients with chronic obstructive pulmonary disease. J Eval Clin Pract. 2011. doi: 10. 1111/j. 1365-2753. 2010. 01617. x.
16. Schols AM, Broekhuizen R, Weling-Scheepers CA, Wouters EF. Body composition and mortality in chronic obstructive pulmonary disease. Am J Clin Nutr. 2005; 82: 53-9.
17. Lenk K, Schuler G, Adams V. Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training. J Cachexia Sarcopenia Muscle. 2010; 1: 9-21.
18. Segurola H, Pérez-Portabella C, Ferrer J, Hermosilla E, Planas M, Burgos R. Muscle wasting in patients with chronic obstructive pulmonary disease (COPD). J Cachexia Sarcopenia Muscle. 2010; 1: 47 (Abstract 009).
19. Lainscak M, Filippatos GS, Gheorghiade M, Fonarow GC, Anker SD. Cachexia: common, deadly, with an urgent need for precise definition and new therapies. Am J Cardiol. 2008; 101: 8E-10E.
20. Lainscak M, Majc Hodoscek L, Düngen HD, Rauchhaus M, Doehner W, Anker SD, et al. The burden of chronic obstructive pulmonary disease in patients hospitalized with heart failure. Wien Klin Wochenschr. 2009; 121: 309-13.
21. Lainscak M, Andreas S, Scanlon PD, Somers VK, Anker SD. Ghrelin and neurohumoral antagonists in the treatment of cachexia associated with cardiopulmonary disease. Intern Med. 2006; 45: 837.
22. Koehler F, Doehner W, Hoernig S, Witt C, Anker SD, John M. Anorexia in chronic obstructive pulmonary disease-association to cachexia and hormonal derangement. Int J Cardiol. 2007; 119: 83-9.
23. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004; 350: 1005-12.
24. Farkas J, Kosnik M, Zaletel-Kragelj L, Flezar M, Suskovic S, Lainscak M. Distribution of self-rated health and association with clinical parameters in patients with chronic obstructive pulmonary disease. Wien Klin Wochenschr. 2009; 121: 297-302.
25. Farkas J, Kosnik M, Flezar M, Suskovic S, Lainscak M. Self-rated health predicts acute exacerbations and hospitalisations in patients with COPD. Chest. 2010; 138: 323-30.
26. Imai K, Gregg EW, Chen YJ, Zhang P, de Rekeneire N, Williamson DF. The association of BMI with functional status and self-rated health in US adults. Obesity. 2008; 16: 402-8.
27. Schembri S, Anderson W, Morant S, Winter J, Thompson P, Pettitt D, et al. A predictive model of hospitalisation and death from chronic obstructive pulmonary disease. Respir Med. 2009; 103: 1461-7.
28. Steer J, Gibson GJ, Bourke SC. Predicting outcomes following hospitalization for acute exacerbations of COPD. QJM. 2010; 103: 817-29.
29. Stolz D, Christ-Crain M, Morgenthaler NG, Leuppi J, Miedinger D, Bingisser R, et al. Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. Chest. 2007; 131: 1058-67.
30. van Hees HWH, Linkels M, Pigmans CJC, Dekhuijzen PNR, Heunks LMA. Akt activation is not reduced in the diaphragm of emphysematous hamsters. J Cachexia Sarcopenia Muscle. 2010; 1: 65 (Abstract: 049).
31. Kamiide Y, Sugiyama M, Tamaki C, Matsuo T, Takagi H, Furuya M. Effect of SUN11031 (a synthetic human ghrelin) on pulmonary and systemic abnormalities in the cigarette smoke-induced chronic obstructive pulmonary disease (COPD) model. J Cachexia Sarcopenia Muscle. 2010; 1: 67 (Abstract: 056).
32. Gertner JM, Oo C. Performance improvement in chronic obstructive pulmonary disease (COPD) cachexia with SUN11031 (a synthetic human ghrelin) in a placebo-controlled trial. J Cachexia Sarcopenia Muscle. 2010; 1: 100 (Abstract: 128).
33. Rabe KF, Hurd S, Anzueto A, et al. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007; 176: 532-55.
34. Calverley PM, Anderson JA, Celli B, et al. TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007; 356: 775-89.
35. Dransfield MT, Rowe SM, Johnson JE, et al. Use of beta blockers and the risk of death in hospitalised patients with acute exacerbations of COPD. Thorax. 2008; 63: 301-5.
36. Sridhar M, Taylor R, Dawson S, Roberts NJ, Partridge MR. A nurse led intermediate care package in patients who have been hospitalised with an acute exacerbation of chronic obstructive pulmonary disease. Thorax. 2008; 63: 194-200.
37. van Wetering CR, Hoogendoorn M, Broekhuizen R, et al. Efficacy and costs of nutritional rehabilitation in muscle-wasted patients with chronic obstructive pulmonary disease in a community-based setting: a prespecified subgroup analysis of the INTERCOM trial. J Am Med Dir Assoc. 2010; 11: 179-87.
38. Lan CC, Yang MC, Lee CH, et al. Pulmonary rehabilitation improves exercise capacity and quality of life in underweight patients with chronic obstructive pulmonary disease. Respirology. 2011; 16: 276-83. doi: 10. 1111/j. 1440-1843. 2010. 01895. x.
39. von Haehling S, Morley JE, Coats AJ, Anker SD. Ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia and Muscle. J Cachexia Sarcopenia Muscle. 2010; 1: 7-8.